clinical trial · NCT04327973
Expanded Access for ATB200/AT2221 for the Treatment of IOPD
Pompe Disease Infantile-OnsetATB200AT2221
brief summary
This is an expanded access program (EAP) for eligible participants designed to provide access to ATB200/AT2221.
started
—
primary completion
—
completion
—
last updated
Oct 27, 2026
detailed description
This program is being offered on a patient by patient basis.
official title
Expanded Use Of Recombinant Human Acid Alpha-Glucosidase/N-butyl-deoxynojirimycin (ATB200/AT2221) For Patients With Infantile-Onset Pompe Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol